Immuron IMRN
NASDAQ IMRN
$1.77 -0.07 (-3.80%)
As of: Sep 9, 2026 · 3:59 PM EDT

Immuron (IMRN) Other Non Operating Income (2018 - 2024)

Immuron (IMRN) posted Other Non Operating Income of -$183.93 for Q3 2024, up 98.99% on a QoQ basis from -$18191.1 in Q2 2024.

Analysis

Immuron (IMRN) Other Non Operating Income (2018 - 2024) Analysis & Trends

Immuron has reported Other Non Operating Income for 5 years, with the latest figure at -$183.93 in Q3 2024.

  • On a quarterly basis, Other Non Operating Income changed N/A year-over-year to -$183.93 in Q3 2024; TTM through Sep 2024 was -$815233.7, a N/A change from a year earlier, with the FY2025 full-year figure at $121.83, changed N/A from the prior year.
  • Other Non Operating Income was -$183.93 for Q3 2024 at Immuron, up from -$18191.1 in the prior quarter.
  • The five-year high for Other Non Operating Income was $236780.9 in Q4 2023, with the low at -$1.0 million in Q2 2021.
  • Average Other Non Operating Income over 3 years is -$203808.4, with a median of -$9187.5 recorded in 2024.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Amgen 211.73 Bn 197.74 Bn 7.24 Bn
2 Gilead Sciences 180.92 Bn 177.74 Bn 6.22 Bn
3 Vertex Pharmaceuticals 132.16 Bn 124.30 Bn 2.84 Bn
4 Regeneron Pharmaceuticals 82.89 Bn 74.90 Bn 3.93 Bn
5 Argenx Se 61.41 Bn 56.23 Bn 1.37 Bn
6 Moderna 53.99 Bn 48.85 Bn 52.00 Mn
7 Alnylam Pharmaceuticals 34.48 Bn 31.18 Bn 992.69 Mn
8 Biogen 31.15 Bn 29.86 Bn 1.96 Bn
9 Roivant Sciences 30.05 Bn 30.05 Bn 1.16 Mn
10 Immuron 10.28 Mn 1.26 Mn -
Historic Data

Historic Data

Download Data
DateValue
Sep 9, 2024 -183.93
Jun 30, 2024 -18,191.05
Dec 31, 2023 236,780.86
Jun 30, 2021 -1.03 Mn
Dec 31, 2019 44,330.00
Dec 31, 2018 257,501.00